Featured News

Does living with celiac disease impact your daily life? We need your help to advance celiac disease research and test an investigational medication.  

We have an important opportunity for Massachusetts residents to contact their legislators today in support of two timely pieces of legislation. In January of 2026, the CAPE Act and the…

Is celiac disease holding you back? If so, consider joining the FB102-301 study for people who have celiac disease who are currently on a gluten-free diet. The phase 2 FB102-301 study is researching a potential new…

Two bills introduced in the Massachusetts legislature last week aim to address long-standing gaps in the diagnosis of celiac disease and the ability for children with this chronic autoimmune condition…

A new study from researchers at the University of Seville’s Department of Microbiology and Parasitology in Spain brings much-needed clarity to a question that has concerned many in the celiac…

Halloween is just around the corner, and this year the Celiac Disease Foundation is proud to partner again with our friends at Food Allergy Research & Education (FARE) to promote…

Is celiac disease having a significant impact on your daily life? You may be eligible for a clinical study. The ASPIRION study is a phase 2 study looking into a new, investigational study drug (amlitelimab) for patients with celiac disease.

New Phase 2 Clinical Trial: TEV-CeD2 Study

A Promising Step Toward Safer Wheat for Celiac Disease We are proud to share the results of a three-year study funded by the Celiac Disease Foundation, recently published in the…

The ILLUMINATE-101 Study is a phase 2 clinical research study evaluating the safety and effectiveness of an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.